Wan Bond: Announcement on the establishment of a wholly-owned subsidiary
Wan Bond: 20.82 million Bond research activity information 20241121
Wan Bond: Notice on Wholly-owned Subsidiary Drugs Obtaining Conformity Evaluation Registration Approval
Wan Bond: Report for the third quarter of 2024
Wan Bond: Announcement on Abnormal Fluctuations in Stock Trading
Wan Bond: Announcement on the Resignation of Director and Chief Financial Officer
Wan Bond: Summary table of non-operating capital usage and other related capital transactions for the first half year
Wan Bond: 2024 semi-annual financial report
Wan Bond: 2024 Semi-Annual Report
Wan Bond: 2024 Semi-Annual Report Summary
Wanbangde Pharmaceutical Holding Group: Announcement of the resolutions of the Ninth Meeting of the Ninth Board of Directors.
Wanbangde Pharmaceutical Holding Group: Announcement on the signing of the "Compensation Agreement for the Acquisition of Houses on State-owned Land" by the subsidiary.
Wanbangde Pharmaceutical Holding Group: Announcement of Annual Equity Distribution Implementation in 2023
Wanbangde Pharmaceutical Holding Group: Announcement on the subsidiary's products being certified as orphan drugs by the US FDA
Wanbangde Pharmaceutical Holding Group: Guohao Lawyer (Hangzhou) Firm's Special Inspection Opinions on the Company's Actual Controller's Increased Shareholding
Wanbangde Pharmaceutical Holding Group: Announcement on the implementation results of the company's actual controller's plan to increase the company's share holdings
Wanbangde Pharmaceutical Holding Group: Wan Bond's 2023 Annual General Meeting of Shareholders Legal Opinion
Wanbangde Pharmaceutical Holding Group: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Wanbangde Pharmaceutical Holding Group: Notice on convening the 2023 Annual General Meeting of Shareholders (after correction)
Wanbangde Pharmaceutical Holding Group: Corrective Notice Concerning the Notice of Convening the 2023 Annual General Meeting of Shareholders
No Data